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MethotrexateStroke is a critical emergency situation in neurological acute medical care, requiring quick assessment and
decision as to when to apply thrombolysis. To avoid unnecessary thrombolytic treatment and potential
complications it is mandatory to be aware of the possible differential diagnoses. We describe the case of a
thirty-year-old man with a subacute leukoencephalopathy following high-dose methotrexate treatment which
resembled a stroke in terms of clinical presentation and MR-tomography.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Case report
A 30-year-old patient suffering from a post-radiation osteosarcoma
of the sacrum had been under oncological treatment, receiving
polychemotherapy with Doxorubicin, Cisplatin and Methotrexate
(EURAMOS-1-Protocol) since July 2014. (See Figs. 1– 3.)
The patient was ﬁrst diagnosed with Ewing sarcoma of the sacrum
in 2000 and underwent resection of the sacrum, polychemotherapy
(EUROEWING protocol 99) and radiation therapy (54 gy) in 2001.
He suffered a pulmonary recurrence in 2004.
In 2005 the right pulmonary middle lobe was resected followed
by chemotherapy with topotecan and cyclophosphamide as well as
radiation therapy (18 gy). Vinblastine and cyclophosphamide were
administered as maintenance therapy in accordance with the CWS
protocol. (Cooperative Soft Tissue Sarcoma Study Group (CWS).1
Between August 2005 and May 2014 no oncological treatment
had been carried out. In June 2014 the diagnosis of post-radiogenic
osteoblastic osteosarcomawasmade. Systemic intravenous chemother-
apy was then commenced. The ﬁrst dose of MTX (12 g/m2) was
administered on the 1st of August 2014 under supportive leucovorin
therapy and the second (12 g/m2) on the 11th of August 2014.
The patient tolerated both treatments well, without side effects or
delayed MTX clearance.S) of the Society for Paediatric
optimization of the diagnostics,
comas and tumors for nearly 30
-cws-studie&id=889%2Frobots.
. This is an open access article underIn the evening of the 18th of August, 7 days after the secondMetho-
trexate course, he was admitted to hospital with a mild hemiparesis on
the right side and hemihypesthesia and paresthesia of subacute onset.
The ﬁrst symptoms occurred in themorning with a feeling of heaviness
and acroataxia of the right upper limb, followed by sensible deﬁcits and
gait disturbance duringmidday. However, on neurological examination
the motor deﬁcits demonstrated frequent ﬂuctuation and subsided
during the course of a few hours.
A CT-scan of the brain with CT-angiography demonstrated no signs
of ischemia, cerebral bleeding, occlusion or other pathology of the
cerebral vessels. In the evening of the same day the patient developed
a mild dysarthria and right-sided central facial palsy. However these
symptoms completely resolved within a few hours, there for a TIA was
suspected. AMRI-Scan of the brainwas carried out, revealing a diffusion
deﬁcit, mainly, but not entirely in the left hemisphere, located in the
semi-oval center, with a corresponding decrease on ADC-maps. Doppler
sonography of the cerebral vessels did not demonstrate any stenosis,
occlusion or vasospasm.
2. Discussion
Methotrexate is well known for its neurotoxicity. It is an anti-
metabolite drug, which inhibits the enzyme dihydrofolate reductase,
preventing the conversion of folic acid to tetrahydrofolic acid and
inhibiting cell replication. It is used in treatment of cancer and autoim-
mune diseases.Many adverse effects of the central nervous systemhave
been described: aseptic meningitis, transverse myelopathy, peripheral
neuropathy, cerebellar syndrome and stroke like syndromes. In
addition, reversible posterior leukoencephalopathy syndrome (PRES)
with hypertensive crisis and cortical blindness has been reported,
especially following intrathecal administration, but also with low dosethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. No changes in FLAIR sequence. Fig. 3. Corresponding hypointensities on the ADC-map.
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varies considerably. It includes acute formswith stupor, agitation und sei-
zures, and chronic forms with cognitive disorders as well as stroke like
syndromes with ﬂuctuating neurological deﬁcits, as demonstrated in
our case [4]. Especiallywhen presentingwith a sudden onset of neurolog-
ical deﬁcits like hemiparesis, paresthesia or aphasia, it is indistinguishable
from ischemic or hemorrhagic stroke.
MTX was ﬁrst used in children with acute lymphoblastic leukemia,
therefore most cases have been reported in children. The incidence of
neurotoxicity depends on the dose, frequency and route of application.
The incidence of acute neurotoxicity has been estimated at 95 out of
1218 cases (7.8%) in children with B-precursor acute lymphoid leukemia
[5]. The extent of the leukoencephalopathy increaseswith theMethotrex-
ate dose, delayed clearance, intrathecal route and frequency ofFig. 2. Bihemispheric areas of restricted diffusion on b1000.administration. The exact mechanism of neurotoxicity is not fully under-
stood [6,7].
The MRI ﬁndings resemble those of ischemic stroke: they are
characterized by hyperintensities of the white matter on diffusion
weighted MRI (DWI) with corresponding hypointensities on ADC-
maps, indicating cytotoxic edema, accompanied by normal MRA and
MRV [8]. Baehring et al. present 27 reports of stroke-like episodes
with typical MRI ﬁndings in patients received methotrexate, introduc-
ing the term “delayed leukoencephalopathy (DLEPS) [9]”.
These similarities illustrate the difﬁculty in differentiating between
the two entities. Acute MTX toxicity is an important consideration in
the differential diagnosis of stroke. Especially in young patients without
cardiovascular risk proﬁle, this entity should be taken into the differential
diagnosis and thrombolysis should be withheld.
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